TCR2 THERAPEUTICS CEO Garry Menzel's 2018 pay jumps 301% to $3.2M
TCR2 THERAPEUTICS reports 2018 executive compensation
By ExecPay News
Published: August 28, 2019
TCR2 THERAPEUTICS reported fiscal year 2018 executive compensation information on August 28, 2019.
In 2018, three executives at TCR2 THERAPEUTICS received on average a compensation package of $1.8M, a 256% increase compared to previous year.
Average pay of disclosed executives at TCR2 THERAPEUTICS
Garry Menzel, Chief Executive Officer, received $3.2M in total, which increased by 301% compared to 2017. 75% of Menzel's compensation, or $2.4M, was in option awards. Menzel also received $344K in non-equity incentive plan and $436K in salary.
Alfonso Quintás Cardama, Chief Medical Officer, received a compensation package of $1.1M, which increased by 340% compared to previous year. 44% of the compensation package, or $502K, was in option awards.
Robert Hofmeister, Chief Scientific Officer, earned $1M in 2018, a 127% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on August 28, 2019.